Evercore ISI raised the firm’s price target on Caribou Biosciences (CRBU) to $13 from $11 and keeps an Outperform rating on the shares. While CD19 and BCMA data look “promising,” funding remains a hurdle for launching pivotal studies, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBU:
- Caribou Biosciences: Advancing Allogeneic Cell Therapy Pipeline and Pivotal Trial Plans Support High-Risk Buy Rating
- Drug Pricing Reforms Threaten Caribou Biosciences’ Future Margins and Market Access
- Caribou Biosciences reports Q4 EPS (28c) vs. (39c) last year
- Here is a List of Small-Cap Biotech ETFs to Watch for Big Gains in 2026
- Caribou Biosciences initiated with a Buy at Clear Street